Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Jan 26, 2022 10:19pm

138 Views

Post# 34365302

RE:News

"The Company’s principal intended use for the proceeds from the initial tranche of funds that will be received from Alumina is for payment of remaining costs of the Company’s Phase 1 clinical study of R-107, which study the Company expects to complete during Q1 this year."
Quote from today's update last paragraph

Is this why we are waiting to start Phase 1? How does that work ? Phase 1 can typically cost between $4 to as much as $6 Million US .

The tax rebate was 880 AUD, Obsidian maybe $2 million US is first 2 tranches, does Bob have enough cash ?

Be nice to see if anyone knows the definite answer.

Otherwise a positive update.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages